Sylvester Comprehensive Cancer Center

  • MAPS - Abramowitz, Matthew

  • Investigator:
    Matthew Abramowitz
    RCname Email

    Coordinator:
    RCemailImg Pavel Noa Hechavarria
    RCphone 3052431036

    IRB: 20101056

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    A Phase II Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

    Eligibility Criteria - NCT01411345 *This information has been extracted from " www.clinicaltrials.gov"

  • HEAT - Abramowitz, Matthew

  • Investigator:
    Matthew Abramowitz
    RCname Email

    Coordinator:
    RCemailImg Milad Al Troudy El Troudi

    IRB: 20110491

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: PROSTATE CANCER FOUNDATION

    Enrolling Sites:

    Deerfield
    Gables
    Northern Sydney Local Health District
    Sylvester
    University Hospital Trust of Turin

    Title:

    A Randomized Study of Radiation Hypofractionation via Extended versus Accelerated Therapy (HEAT) For Prostate Cancer

    Eligibility Criteria - NCT01794403 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200863 - Abramowitz Matthew

  • Investigator:
    Matthew Abramowitz
    RCname Email

    Coordinator:
    RCemailImg Pavel Noa Hechavarria
    RCphone 3052431036

    IRB: 20200863

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: Johns Hopkins University

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    A Phase II Randomized Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)

    Eligibility Criteria - NCT04037358 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201533 - Benedetto Pasquale

  • Investigator:
    Pasquale Benedetto
    RCname Email

    Coordinator:
    RCemailImg Ray Lewis
    RCphone +1 (305) 2434033

    IRB: 20201533

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Kidney

    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] A031704

    Eligibility Criteria - NCT03793166 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211217 - Bilusic Marijo

  • Investigator:
    Marijo Bilusic
    RCname Email

    Coordinator:

    IRB: 20211217

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: Surface Oncology

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer.

  • 20220121 - Bilusic Marijo

  • Investigator:
    Marijo Bilusic
    RCname Email

    Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20220121

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: MERCK SHARP & DOHME

    Enrolling Sites:

    Sylvester

    Title:

    Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

    Eligibility Criteria - NCT02861573 *This information has been extracted from " www.clinicaltrials.gov"

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue

    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200056 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20200056

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid

    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester

    Title:

    A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"

  • 20170004 - Gonzalgo Mark

  • Investigator:
    Mark Gonzalgo
    RCname Email

    Coordinator:

    IRB: 20170004

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    Randomized Clinical Trial of Intra-corporal vs Extra-corporal Urinary Diversion after Robot Assisted Radical Cystectomy

    Eligibility Criteria - NCT03469362 *This information has been extracted from " www.clinicaltrials.gov"

  • QUILTT-3.032 - Gonzalgo, Mark

  • Investigator:
    Mark Gonzalgo
    RCname Email

    Coordinator:

    IRB: 20170350

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder

    Sponsor: ALTOR BIOSCIENCE CORP

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    CA-ALT-803-01-16: QUILT-3.032 - A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

    Eligibility Criteria - NCT03022825 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200017 - Libardi Dal Pra Alan

  • Investigator:
    Alan Libardi Dal Pra
    RCname Email

    Coordinator:

    IRB: 20200017

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: SCCC

    Enrolling Sites:

    Gables
    JMH
    Sylvester

    Title:

    A Pilot Study Using a Digital Behavioral Intervention with a Smart Water Bottle to Improve Bladder Filling Compliance in Prostate Cancer Patients Undergoing Radiation Therapy

    Eligibility Criteria - NCT04946214 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • PT2977-201 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:

    IRB: 20180954

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Kidney

    Sponsor: Peloton

    Enrolling Sites:

    Sylvester

    Title:

    PT2977-201 : A Phase 2 Trial of PT2977 in Combination With Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

    Eligibility Criteria - NCT03634540 *This information has been extracted from " www.clinicaltrials.gov"

  • RTX-240-01 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200686

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Multiple

    Sponsor: Rubius Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB

    Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"

  • 20170656 - Penedo Frank

  • Investigator:
    Frank Penedo
    RCname Email

    Coordinator:

    IRB: 20170656

    SDG: Population Sciences
    Disease Site(s):

    Prostate

    Sponsor: SCCC

    Enrolling Sites:

    Community Clinics
    Deerfield
    Gables
    Hollywood
    Kendall
    NorthWestern University
    Plantation
    Sylvester

    Title:

    Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer

    Eligibility Criteria - NCT03344757 *This information has been extracted from " www.clinicaltrials.gov"

  • Tbio-6517-ITu-001 - Pimentel, Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20200277

    SDG: Colorectal Cancer
    Disease Site(s):

    Multiple

    Sponsor: TSB

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors

    Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"

  • The Miami BLaStM Trial - Pollack, Alan

  • Investigator:
    Alan Pollack
    RCname Email

    Coordinator:
    RCemailImg Pavel Noa Hechavarria
    RCphone 3052431036

    IRB: 20140627

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    JMH
    Sylvester

    Title:

    A Phase II Randomized Trial of MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy ? The Miami BLaStM Trial

    Eligibility Criteria - NCT02307058 *This information has been extracted from " www.clinicaltrials.gov"

  • COMPPARE - Pollack, Alan

  • Investigator:
    Alan Pollack
    RCname Email

    Coordinator:

    IRB: 20190275

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: PCORI

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    COMPPARE: ?A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in Prostate CancEr.

    Eligibility Criteria - NCT03561220 *This information has been extracted from " www.clinicaltrials.gov"

  • SWOG S1802 - Ritch, Chad

  • Investigator:
    Chad Ritch
    RCname Email

    Coordinator:

    IRB: 20180970

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: SWOG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    S1802: PHASE III RANDOMIZED TRIAL OF STANDARD SYSTEMIC THERAPY (SST) VERSUS STANDARD SYSTEMIC THERAPY PLUS DEFINITIVE TREATMENT (SURGERY OR RADIATION) OF THE PRIMARY TUMOR IN METASTATIC PROSTATE CANCER

    Eligibility Criteria - NCT03678025 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220331 - Ritch Chad

  • Investigator:
    Chad Ritch
    RCname Email

    Coordinator:

    IRB: 20220331

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Other Male Genital

    Sponsor: ECOG

    Enrolling Sites:

    Sylvester

    Title:

    EA8134: InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative study)

  • RPL-001-16 - Rodriguez, Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20180802

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Breast-Female,Colon,Melanoma, skin

    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester

    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • DST-2970 - Sharma, Janaki

  • Investigator:
    Janaki Sharma
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200540

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: DISPERSOL TECH

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate

    Eligibility Criteria - NCT04291664 *This information has been extracted from " www.clinicaltrials.gov"

  • SPN-00714 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20190673

    SDG: Other
    Disease Site(s):

    Breast,Colon,Esophagus,Kidney,Lung,Other Female Genital,Ovary,Stomach

    Sponsor: MTEM

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"